KOMBIGLYZE XR 2.5 mg/1 (Saxagliptin and Metformin Hydrochloride TABLET, FILM COATED, EXTENDED RELEASE) 2.5 mg/1

KOMBIGLYZE XR 2.5 mg/1 combines saxagliptin and metformin hydrochloride for extended-release blood sugar management. This oral medication supports glucose control in adults with type 2 diabetes.

Strength

2.5 mg/1

Pack Size

60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0310-6125-60)

Manufacturer / TM Owner

AstraZeneca Pharmaceuticals LP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KOMBIGLYZE XR 2.5 mg/1 is used to manage blood sugar levels in adults with type 2 diabetes. This extended-release tablet combines saxagliptin and metformin hydrochloride to help regulate glucose. It is typically prescribed alongside diet and exercise for comprehensive diabetes management.

Side Effects

Common effects of KOMBIGLYZE XR 2.5 mg/1 may include gastrointestinal discomfort, headache, or mild dizziness. Some users report fatigue or nasal congestion. These effects vary and are not experienced by everyone.

Precautions & Warnings

Handle KOMBIGLYZE XR 2.5 mg/1 with care, especially if you have kidney or liver issues. Avoid alcohol and stay hydrated. Consult a healthcare provider before use if you have medical conditions or are pregnant.

Avoid Interactions

KOMBIGLYZE XR 2.5 mg/1 may interact with certain medications, including diuretics, NSAIDs, or other diabetes treatments. Alcohol and some supplements can also affect its efficacy. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

KOMBIGLYZE XR 2.5 mg/1 is used to manage blood sugar levels in adults with type 2 diabetes.

KOMBIGLYZE XR 2.5 mg/1 is an oral medication taken as directed by a healthcare provider, typically once daily.

Common side effects may include gastrointestinal discomfort, headache, or mild dizziness.

KOMBIGLYZE XR 2.5 mg/1 may interact with certain medications, so consult a healthcare provider before combining it with other treatments.

KOMBIGLYZE XR 2.5 mg/1 should be used with caution in individuals with kidney or liver issues, and pregnant women should consult a healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.